Hip Study: Smith & Nephew touts study results for new metal-on-metal implant
March 13, 2012 by MassDevice staff
Smith & Nephew unveils the results of its FDA-requested metal-on-metal hip
resurfacing implant study, finding that 99% of participants were either
satisfied or extremely satisfied with their implants at 10 years.
British orthopedic titan Smith & Nephew (NYSE:SNN) touted the results of a
10-year study of its metal-on-metal hip resurfacing implants, hoping to
differentiate its implants from the high-profile recall of rival DePuy’s ASR
Smith & Nephew, one of the largest metal-on-metal hip implant makers, is
looking to limit the collateral damage to its Birmingham hip resurfacing system
from the Johnson & Johnson (NYSE:JNJ) subsidiary’s ASR recall. J&J is facing
down a slew of patient injury lawsuits, not to mention scientists warning of
possible toxicity and bone destruction related to the implants and researchers
urging the FDA to ban the devices entirely.
Smith & Nephew’s latest data, from a study it ran at the request of the FDA,
found that 99% of the U.K. 400 patients followed were either satisfied or
extremely satisfied with their Birmingham hip after 10 years, according to a
"The fact is that the BHR hip is not like other metal-on-metal hip implants,"
global hip franchise senior vice president John Soto said in prepared remarks.
"It really is in a class all its own – it’s safe and effective, and is the best
choice for the right patient."
The headline-making J&J recall has drawn other artificial hip makers into the
fire, including including Biomet Inc., Stryker Corp. (NYSE:SYK) and Zimmer
Holdings Inc. (NYSE:ZMH), all of which were asked by the FDA to run post-market
studies of their hip replacements.